Press releases

2010

Topic

14 April	Synosia announces SYN-115 Improves Motor and Non-Motor Function in Patients with Mild- to-Moderate Parkinson’s Disease
	SYN-115 von Synosia Therapeutics verbessert motorische und nicht motorische Funktionen bei Patienten mit leichter bis mittelschwerer Parkinsonkrankheit

01 February	Synosia Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson’s Disease
	Synosia meldet positive Zwischenergebnisse für potenzielle First-in-class-Therapie bei Parkinson-Krankheit

Media Enquiries

Julie Walters
Tudor Reilly (Europe)
Tel: +44 (0) 1494 687860
Mobile: +44 (0) 775 3626967
Email: julie.walters@tudor-reilly.com

Michele Parisi
Tudor Reilly (US)
Tel: +1 925 864 5028
Email: michele.parisi@tudor-reilly.com

Download Company Brochure PDF
Get the fast facts on Synosia

EMAIL REGISTRATION
Sign up for regular updates
on Synosia.

Synosia Therapeutics adopts a privacy policy and will not disclose your email address or details to any third party.

Action you wish to take:

Your email address: